What is Demetrix?
Founded in 2015 and headquartered in Berkeley, California, Demetrix is at the forefront of scientific innovation in the health and wellness industry. The company specializes in the production of high-purity, rare cannabinoids, leveraging advanced science to create products for both pharmaceutical and consumer markets. Demetrix boasts a distinguished team of experts spanning research and development, production, regulatory affairs, and commercialization, bringing extensive experience in bringing fermentation-derived products to market. The company's commitment to science-backed wellness solutions positions it as a key player in the evolving biotechnology landscape.
How much funding has Demetrix raised?
Demetrix has raised a total of $61M across 2 funding rounds:
Angel/Seed
$11M
Series A
$50M
Angel/Seed (2019): $11M with participation from Horizons Ventures
Series A (2019): $50M led by Tuatara Capital and Horizons Ventures
Key Investors in Demetrix
Horizons Ventures
Horizons Ventures is a venture capital firm with over 20 years of experience supporting entrepreneurs in transforming startup ventures into successful companies. They are known for their active involvement and equity financing, partnering with visionary and pragmatic entrepreneurs.
Tuatara Capital
Tuatara Capital is a firm dedicated to backing innovative entrepreneurs in transformative industries. They provide expert guidance and resources throughout a company's life cycle, focusing on navigating complex regulatory and commercial landscapes to foster growth-stage companies.
What's next for Demetrix?
The recent major strategic investment in Demetrix signals a pivotal phase for the company, likely aimed at accelerating product development, expanding manufacturing capabilities, and broadening market penetration. With a foundation built on scientific rigor and a clear focus on rare cannabinoids, Demetrix is poised to capitalize on the growing demand for scientifically validated health and wellness products. Future endeavors may include further research into novel cannabinoid applications, strategic partnerships within the pharmaceutical sector, and scaling production to meet increasing global demand. This strategic financing is expected to fuel innovation and solidify Demetrix's position as a leader in its specialized niche.
See full Demetrix company page
